Financial Sense Advisors Inc. Has $848,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Financial Sense Advisors Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 49.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,472 shares of the biopharmaceutical company's stock after acquiring an additional 11,081 shares during the quarter. Financial Sense Advisors Inc.'s holdings in Pfizer were worth $848,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter valued at approximately $28,000. Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth approximately $30,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 3.6%

Shares of PFE stock traded up $0.87 on Tuesday, hitting $25.13. The stock had a trading volume of 48,049,307 shares, compared to its average volume of 41,933,366. The firm has a market cap of $142.84 billion, a P/E ratio of 18.21, a PEG ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a fifty day moving average price of $24.07 and a two-hundred day moving average price of $24.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.85%. Pfizer's payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Redburn Atlantic decreased their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Morgan Stanley increased their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, TD Cowen reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.